ClinicalTrials.gg
CompletedNCT06092684Updated Jul 29, 2024

The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

A Phase 3 interventional study of BT-KTM-I and Ketanest®S in Laparoscopy and Anesthesia, Intravenous, sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd.. Completed at 12 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective is to evaluate the efficacy and safety of BT-KTM-I(Esketamine Hydrochloride Injection produced by Chengdu Brilliant Pharmaceutical Co., Ltd.) for general anesthesia, using the Originator drug Ketanest®S(Esketamine Hydrochloride Injection) as a positive control.

Read the detailed description

This is a multicenter, randomized, double-blind, positive drug parallel controlled clinical trial, planned to include 358 subjects, including 179 in the experimental group and 179 in the control group. The entire study was divided into a screening period, surgery day, and follow-up observation period. The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h. The experiment used vital signs, physical examination, laboratory examination, 12-lead electrocardiogram examination, and adverse events/serious adverse events for safety evaluation.

02

Conditions studied

  • Laparoscopy
  • Anesthesia, Intravenous
03

In context

Lead sponsor

Chengdu Brilliant Pharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range from 18 to 60 years old (including threshold), regardless of gender;
  2. Patients undergoing elective general anesthesia laparoscopic surgery (only tracheal intubation mechanical ventilation), 1 hour ≤ expected anesthesia time ≤ 2.5 hours;
  3. The (ASA) score of Class I or II;
  4. 18kg/m2\<\<30kg/m2;
  5. The subjects understand the purpose and procedure of this experiment, voluntarily participate in this experiment, and sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to general anesthesia, or those who have had previous anesthesia accidents;
  2. Known intolerance or allergy to ketamine hydrochloride, esketamine hydrochloride, propofol, rocuronium bromide, opioids, neostigmine, atropine, belladonnae alkaloids;
  3. Long-term (continuous or intermittent) use of benzodiazepines sleeping pills, opioid analgesics, or use of narcotic analgesics within 24 hours before randomization or use of narcotic drugs within 7 days;
  4. Have a history of increased intraocular pressure (such as glaucoma) or puncture eye injury;
  5. Patients with a history of asthma;
  6. Patients with mental system diseases (schizophrenia, mania, insanity, etc.) or cognitive disorders;
  7. Patients with a history of craniocerebral injury, possible presence of intracranial hypertension, cerebral aneurysm, cerebrovascular accident, and central nervous system disease;
  8. Have a serious history of cardiovascular diseases (such as myocardial ischemia, heart failure and severe arrhythmia); Angina pectoris (unstable angina) caused by insufficient blood supply to the coronary arteries of the heart, or myocardial infarction occurring within the first 6 months before screening;
  9. Hypertensive patients with systolic blood pressure still ≥ 140mmHg and/or diastolic blood pressure still ≥ 90mmHg after treatment with antihypertensive drugs;
  10. Diabetic patients whose blood glucose was not satisfactorily controlled (fasting blood glucose ≥11.1mmol/L during the screening period);
  11. Severe lipid metabolism abnormalities (such as triglycerides>5mmol/L, diabetic hyperlipidemia, familial hypercholesterolemia, lipoid nephropathy, acute pancreatitis with hyperlipidemia, etc.);
  12. Have a history of hyperthyroidism;
  13. Have a history of drug use within 2 years before screening;
  14. Individuals with a history of alcohol abuse within 2 years before screening. alcoholism is defined as drinking more than 14 units of alcohol per week (1 unit =360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or acute alcoholism or alcohol dependence;
  15. Participants in any clinical trial (defined as receiving the experimental drug or placebo) within 3 months prior to screening;
  16. Patients with respiratory management difficulties as determined by the investigators (modified Markov score level Ⅳ);
  17. Abnormal coagulation function (PT or PT- ≥ 1.5×, APTT ≥ 1.5×ULN), or with bleeding tendency (such as active digestive ulcer) or undergoing thrombolytic or anticoagulant treatment;
  18. Anemia or thrombocytopenia (≤80×109/L, HGB≤90g/L);
  19. Abnormal liver function [ and (or) AST≥1.5×ULN, ≥1.5×ULN];
  20. Abnormal renal function (BUN≥1.5×ULN; Cr≥1.2×ULN)
  21. Pregnant or lactating women; Women or men with fertility are unwilling to use between the screening period and the end of the trial;
  22. Subjects who are deemed by the investigators to have any other unfavorable factors for participating in this clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    BT-KTM-I

    Patients received 0.5mg/kg BT-KTM-I during anesthesia induction period. Patients received 0.5mg/kg/h BT-KTM-I during anesthesia maintenance period.

    Drug: BT-KTM-I

  • Active comparator
    Ketanest®S

    Patients received 0.5mg/kg Ketanest®S during anesthesia induction period. Patients received 0.5mg/kg/h Ketanest®S during anesthesia maintenance period.

    Drug: Ketanest®S

Interventions

  • The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

    Also known as: Esketamine

  • The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

    Also known as: Esketamine

06

What researchers measure

Primary outcomes

  1. The awakening time from anesthesia

    Time frame: The time from discontinuing the use of anesthetics (propofol) to subjects waking up immediately after surgery (following instructions to open their eyes)

Secondary outcomes

  1. Incidence of adverse reactions in the mental system

    Time frame: Within 60 minutes after the subject wakes up

07

Study locations

12 sites
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
  • Hunan Provincial Maternal and Child Health Care Hospital
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Second Hospital University of South China
    Hengyang, Hunan, China
  • Pidu District People's Hospital, Chengdu
    Chengdu, Sichuan, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan, China
  • The Second People's hospital of Neijiang
    Neijiang, Sichuan, China
  • The Second People's Hospital of Yibin
    Yibin, Sichuan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Mar 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 23, 2023
StartActual
Sep 20, 2023
Primary completionActual
Mar 19, 2024
CompletionActual
Mar 19, 2024
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06092684
Lead sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Sep 20, 2023
Primary completion
Mar 19, 2024
Completion
Mar 19, 2024
Last update
Jul 29, 2024

Study contacts

Wen Ouyang, MD
principal investigator · The Third Xiangya Hospital of Central South University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion